ArticleHereditas2026
miR-3913-3p promoted the progression of lung adenocarcinoma by regulating STX3 expression.
Article in Hereditas, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe prognostic relevance and operational pathways of miR-3913-3p during disease advancement are not entirely clarified. This research intends to thoroughly assess the clinical importance and mechanistic contributions of miR-3913-3p within lung adenocarcinoma (LUAD) contexts.
methodsRelationships linking miR-3913-3p abundance with five-year survival rates were examined through Kaplan-Meier methodology, while prognostic strength was determined by multivariate Cox regression modeling. Quantification of miR-3913-3p and STX3 in clinical specimens and cellular models was accomplished via RT-qPCR. Functional impacts on LUAD cells and regulatory interactions with target genes were validated through cell transfection, CCK-8 assays, Transwell migration/invasion assays, and dual-luciferase reporter assays.
resultsmiR-3913-3p expression was significantly elevated in LUAD tissues compared to matched non-tumor tissues. High miR-3913-3p expression was significantly correlated with poor tumor differentiation, advanced TNM stage, and lymph node metastasis (p < 0.05). Multivariate Cox analysis identified high miR-3913-3p expression as a predictor of poor prognosis (HR = 2.450, 95% CI: 1.014–5.920, p = 0.046). Functionally, miR-3913-3p mimic enhanced the proliferative, migratory, and invasive capacities of LUAD cells, whereas miR-3913-3p inhibitor suppressed these malignant behaviors. Notably, co-transfection with si-STX3 rescued the inhibitory effects induced by the miR-3913-3p inhibitor. Mechanistically, dual-luciferase reporter assays confirmed that miR-3913-3p directly binds to the 3’untranslated region (3’UTR) of STX3, leading to its functional suppression.
conclusionThis study demonstrates the existence of a regulatory miR-3913-3p/STX3 axis in LUAD. miR-3913-3p likely promotes the proliferation, migration, and invasion of LUAD cells by targeting STX3, implicating this axis in LUAD pathogenesis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.